statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that...

Viridian Therapeutics to Participate in Upcoming May Investor Conferences

Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today reported recent...

Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2024 Financial Results

Viridian Therapeutics, Inc. (Nasdaq: VRDN) (the company or Viridian), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare...

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced it will host...

Viridian Therapeutics to Webcast First Quarter 2024 Financial Results on May 8, 2024

VIRIDIAN SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Viridian Therapeutics, Inc. (VRDN) and Encourages Investors to Contact the Firm VIRIDIAN SHAREHOLDER ALERT: Kaskela Law LLC...

VIRIDIAN SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Viridian Therapeutics, Inc. (VRDN) and Encourages Investors to Contact the Firm

For the last three days, A.I.dvisor has detected that VRDN's AroonDown red line is above 70 while the AroonUp green line is below 30 for three straight days. This move could indicate a strong...

Viridian Therapeutics (VRDN, $17.51) Aroon Indicator entered a Downtrend on March 27, 2024.

This is a Bearish indicator signaling VRDN's price could decline from here. Traders may explore shorting the stock or put options...

Viridian Therapeutics (VRDN, $17.55) Moving Average Convergence Divergence (MACD) Histogram turned negative on March 25, 2024

Viridian Therapeutics, Inc. (NASDAQ:VRDN  Get Free Report)s share price fell 4.7% during mid-day trading on Friday after B. Riley lowered their price target on the stock from $29.00 to...

Viridian Therapeutics (NASDAQ:VRDN)  Shares Down 4.7%  After Analyst Downgrade

This is a Bullish indicator signaling VRDN's price could rise from here. Traders may explore going long the stock or buying call options...

Viridian Therapeutics (VRDN, $18.02) Moving Average Convergence Divergence (MACD) Histogram turned positive on March 22, 2024

Viridian Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Its product candidates include Cobomarsen, which treats patients with certain cancers, including cutaneous T-cell lymphoma and adult T-cell leukemia/lymphoma, and Remlarsen and MRG-229, which are made for the treatment of patients with pathological fibrosis. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Waltham, MA.

Watchers	9,312
52-Wk Low	$10.93
52-Wk High	$28.35

Volume	70,780.00
52-Wk High	$28.35
52-Wk Low	$10.93

Period	Estimated	Reported	Surprise	Result
Q2'24	-$0.88	--	--	N/A
Q1'24	-$1.09	-$0.79	27.46%	BEAT
Q4'23	-$0.98	-$1.35	-38.06%	MISSED
Q3'23	-$1.25	-$1.09	12.48%	BEAT
Q2'23	-$1.26	-$1.27	-0.74%	MISSED

VRDN Viridian Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals